SAN DIEGO , Feb. 25, 2015 (GLOBE NEWSWIRE) -- Biocept , Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced that the Company will issue its financial results for the
SAN DIEGO , May 4, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and Circulating Tumor Cells (CTCs), today announced that the Company will issue its financial results for the first
SAN DIEGO , Feb. 9, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA and circulating tumor cells, today announced the pricing of an underwritten public offering of 8,000,000 shares of its
Biocept, Inc. Pioneers Revolutionary Diagnostics Aimed at Personalized Cancer Management We noted earlier this week that San Diego?based Biocept, which is developing advanced cancer diagnostics technology, had recently raised $2.3 million from its investors.
SAN DIEGO , May 7, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular diagnostics company specializing in oncology biomarker detection and monitoring through circulating tumor cells (CTCs) and cell-free circulating tumor DNA, today announced that it has closed a loan facility of up
Biocept further expands its patent estate for capturing and detecting target cells of interest, including circulating tumor cells SAN DIEGO , Jan. 8, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular offerings designed to provide physicians with
Biocept, Inc. Announces Two New Director Appointments Biocept, Inc. (“Biocept”), an emerging leader in biotechnology, announced today the appointment of Daniel H. Petree and M. Faye Wilson as Directors. “We are pleased to welcome Dan and Faye to our Board.
SAN DIEGO, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc., an oncology diagnostics company focused on improving individual patient treatment, today announced the pricing of its initial public offering of 1,900,000 shares of its common stock offered at a price to the public of $10.00 per share.
SAN DIEGO , April 29, 2016 /PRNewswire/ -- Biocept, Inc. (" Biocept ") (Nasdaq: BIOC) today announced that it has priced a registered public offering of an aggregate of approximately 5.0 million shares of common stock at a price to the public of $1.00 per share.
